Skip to main content

Table 6 Summary of fluid balance data (mL)

From: First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

   Remogliflozin etabonate dose
  Placebo 20 mg 50 mg 150 mg 500 mg 1000 mg
Healthy Subjects (n = 10) (n = 8) (n = 8) (n = 8) (n = 8) (n = 8)
-24 h to pre-dose -462 (605) -460 (1311) -338 (525) -512 (731) -278 (1250) -126 (798)
0–12 h post-dose 163 (668) 243 (1161) -570 (582) -86 (909) -159 (531) -273 (331)
12–24 h post-dose -739 (423) -581 (387) -551 (530) -564 (478) -424 (334) -495(367)
T2DM subjects n = 6   n = 6   n = 6  
-24 h to pre-dose -312 (457)   -504 (294)   188 (1879)  
0–12 h post-dose 569 (400)   -78(433)   -29 (749)  
12–24 h post-dose -908 (524)   -803 (658)   -1088(679)  
  1. Fluid balance = total fluid intake minus total urine volume.
  2. Results are expressed as mean (SD).